Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalutrafusp alfa (GS-1423) in Advanced Solid Tumors
NCT03954704Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of dalutrafusp alfa in solid tumor (advanced stage), gastric cancer (GC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Gilead Sciences. Primary endpoints: Dose Limiting Toxicities at 28 days, Safety and Tolerability and 1 more. Started Jun 2019; status: terminated.
02
Drugs
dalutrafusp alfa
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03954704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954704.